ArticleAmerican journal of translational research2023
Diagnostic and prognostic value of serum CircERBB2 level in NSCLC and its correlation with clinicopathological features in NSCLC patients.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.Non-coding RNA research · 2025Review
- Circular RNA circRANGAP1/miR-512-5p/SOD2 Axis Regulates Cell Proliferation and Migration in Non-small Cell Lung Cancer (NSCLC).Molecular biotechnology · 2024Article
- Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the relationship between serum circular RNA ERBB2 (CircERBB2) levels and clinicopathological features and prognosis of patients with non-small cell lung cancer (NSCLC).
methodsIn this retrospective study, 87 patients with NSCLC (NSCLC group) and 85 patients with benign lung disease (benign lung disease group) in the First Affiliated Hospital of Yangtze University from March 2016 to February 2019 were enrolled; in addition, another 87 healthy subjects were selected as the control group. Serum levels of CircERBB2, cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) in each group were detected, and their relationship with the prognosis of NSCLC patients as well as their diagnostic value was analyzed. The serum CircERBB2 levels in NSCLC patients with different clinicopathological characteristics were compared, and the correlation of serum level of CircERBB2 with CircERBB2 as well as CYFRA21-1 was analyzed.
resultsThe serum CircERBB2, CYFRA21-1 and CEA levels in the control group, benign lung disease group and NSCLC group were gradually increased (
conclusionSerum CircERBB2 is highly expressed in NSCLC patients, and closely related to disease progression, so it has good prognostic value.
Indexed as
Identifiers
36915755PMC10006754W4324129774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.